NovaScreen Receives Wyeth Contract for High Throughput Screen

28-Jun-2006

NovaScreen Biosciences Corporation, a Caliper Life Sciences Company, announced that Wyeth Pharmaceuticals, a division of Wyeth, has selected NovaScreen to conduct a high-throughput screening (HTS) campaign. As a result, NovaScreen will screen 500,000 compounds against an inflammatory target.

The HTS campaign combines NovaScreen's kinase profiling expertise with Caliper's LabChip(R) 3000 microfluidic screening platform, which utilizes electrophoretic separation of assay components to provide analytical quality data that is highly reproducible.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances